Vitiligo Repigmentation Achieved in Five Treatments with XTRAC Excimer Laser, Study Suggests
STRATA Skin Sciences Inc announces the publication of an independent study on the treatment of vitiligo using the Company’s XTRAC excimer laser.
STRATA Skin Sciences Inc announces the publication of an independent study on the treatment of vitiligo using the Company’s XTRAC excimer laser.
Research indicates that combining oral antioxidant technology with targeted phototherapy leads to better skin repigmentation and patient quality of life.
Operating with a 16W diode, the platform expands full-body skin revitalization settings across mJOULE and JOULE X systems.
The efficacy of immunomodulators for the treatment of vitiligo is supported by results from a literature review published in Dermatologic Therapy, according to Dermatology Advisor.
Read MoreThe presence of clinical markers in patients with vitiligo may have an association with worsening prognoses and rapid disease progression, according to a perspective cohort study published in JAMA Dermatology.
Read MoreUSA: Topical tofacitinib 2% is effective for the treatment of refractory vitiligo, suggests a recent study published in the British Journal of Dermatology, Specialty Medical Dialogues reports.
Read MoreMicroneedling combined with topical 5-fluorouracil (5-FU) outperformed microneedling alone in the treatment of vitiligo, according to the results of a study, Dermatology Advisor reports.
Read MoreTeVido BioDevices (TeVido) announces the commercial availability of its lead product TruPigment (autologous non-cultured epidermal cell suspension) for the restoration of lost skin color due to vitiligo.
Read MoreCohort study data published in the Journal of the American Academy of Dermatology identifies multiple new disease associations with vitiligo, including multiple sclerosis, idiopathic thrombocytopenic purpura (ITP), and lymphoma.
Read MoreA nationwide phase II clinical trial, coordinated out of Tufts Medical Center in Boston, has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin pigmentation.
Read MoreTreatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Read More